Official ESCRS | European Society of Cataract & Refractive Surgeons
Athens 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings
ATHENS escrs

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Latanoprost 0.005% preservative-free ophthalmic solution(Monoprost) vs Latanoprost 0.005% ophthalmic solution

Poster Details

First Author: A.Pissarakis GREECE

Co Author(s):    P. Bournas   D. Kanellas   K. Pavlakis   M. Zozolou   E. Vaikousis  

Abstract Details

Purpose:

Evaluation of the efficacy, safety and patient satisfaction while using Latanoprost 0.005% preservative-free compared with that of Latanoprost 0.005% in patients with glaucoma or ocular hypertension.

Setting:

Ophthalmic Department ,General Hospital of Nikaia Piraeus ,Greece

Methods:

In 47 patients with glaucoma or ocular hypertension who were treated with Latanoprost 0.005% (monotherapy) was replacement treatment with Latanoprost 0.005% preservative-free . Patient selection criteria were monotherapy for at least 3 months, intraocular pressure (IOP) <22 mmHg, and the non-use of artificial tears. Were recorded visual acuity, visual fields and IOP. The patients answered a questionnaire on tolerance to the drug (redness, foreign body sensation, pruritus, dry eye-Ocular Surface Disease Index OSDI). Review in 4 weeks by measuring IOP in the respective times of day and answer the questionnaire. At 12 weeks was reviewing all the initial parameters put.

Results:

For the 44 patients who completed the study, the initial intraocular pressure was 17.2mmIg, at 4 weeks 16.8 mm Ηg and at 12 weeks 17.1 mmHg. According to the questionnaire was observed improvement of tolerance to the drug. No significant changes in visual acuity and visual fields. 3 patients were excluded

Conclusions:

At 12 weeks, visual acuity, visual fields and IOP showed no significant change. There was significant improvement of tolerance to the drug by the use of Latanoprost 0.005% preservative-free ophthalmic solution. FINANCIAL DISCLOUSRE: NONE

Back to Poster listing